Dog Years DAO ($DOG)
Recent developments:
0% of the initial token allocation is held by the creator.
Creator token stats last updated: Aug 27, 2025 20:23
The following is generated by an LLM:
Summary
canine longevity DAO undermined by zero creator allocation
Analysis
Dog Years DAO presents a novel approach to canine longevity through decentralized clinical trials and follistatin gene therapy. The project's focus on converting clinical data into tiered licensing revenue offers a clear value proposition, and the team includes members with relevant expertise in biohacking, veterinary medicine, and decentralized research. However, critical red flags emerge: the creator holds 0% of the token supply (contrary to typical founder allocations), which severely undermines incentive alignment for a project claiming to be a DAO. The token's utility appears underdeveloped - while contributors earn tokens, the mechanism linking token ownership to governance or value accrual isn't clearly defined. The liquidity pool and token distribution should be urgently verified for signs of sell-offs, as the current information doesn't confirm whether creator wallets have been active. While the scientific premise is compelling, the token structure fails to support the project's ambitions, creating centralization risks and misaligned incentives.
Rating: 0
Generated with LLM: deepseek/deepseek-r1
LLM responses last updated: Aug 27, 2025 20:23
Original investment data:
# Dog Years DAO ($DOG)
URL on launchpad: https://app.virtuals.io/prototypes/0xCfAbd6ddE4d38275cb44BdF4C8EF300f9B665521
Launched at: Wed, 27 Aug 2025 20:22:11 GMT
Launched through the launchpad: Virtuals Protocol
Launch status: UNDERGRAD
## Token details and tokenomics
Token address: 0xCfAbd6ddE4d38275cb44BdF4C8EF300f9B665521
Top holders: https://basescan.org/token/0xCfAbd6ddE4d38275cb44BdF4C8EF300f9B665521#balances
Liquidity contract: https://basescan.org/address/0x8be41BbB3CD29A7eE44d717c781391268D85465C#asset-tokens
Token symbol: $DOG
Token supply: 1 billion
Creator initial number of tokens: Creator initial number of tokens: 0 (0% of token supply)
## Creator info
Creator address: 0xe1490A9Cb6B077CD611e8a7e5427dae526381569
Creator on basescan.org: https://basescan.org/address/0xe1490A9Cb6B077CD611e8a7e5427dae526381569#asset-tokens
Creator on virtuals.io: https://app.virtuals.io/profile/0xe1490A9Cb6B077CD611e8a7e5427dae526381569
Creator on zerion.io: https://app.zerion.io/0xe1490A9Cb6B077CD611e8a7e5427dae526381569/overview
Creator on debank.com: https://debank.com/profile/0xe1490A9Cb6B077CD611e8a7e5427dae526381569
## Description at launch
Can we add years to dogs' lives, and life to their years? Dog Years will lead decentralized clinical trials in pursuit of extending canine healthspan, creating a future where dogs and their humans share longer, healthier lives together.
## Overview
Degenerative disorders cascade: reduced mobility triggers muscle loss, adiposity gain, metabolic decline, and chronic inflammation. All of these, in turn, reduce lifespan.
Follistatin gene therapy offers a breakthrough approach with multiple mechanisms of action. A single administration could provide relief for months. By inhibiting myostatin and activin, follistatin reduces inflammatory cytokines, preserves muscle tissue, and supports cartilage integrity. This shifts treatment from symptom management to addressing underlying aging mechanisms.
Canines are an ideal translational model for human aging. They naturally develop osteoarthritis like humans, share our environment, and experience similar age-related frailty syndromes. We believe that a combination of treatments will drive the most meaningful longevity gains, and that it is on us to develop new ways of performing science to vet them.
By breaking the feedback loop between inflammation and systemic aging, we aim to create effective canine longevity interventions that will inform human therapeutic development.
Value Capture Model
Dog Years DAO will convert clinical data into sustainable value through tiered licensing. The initial dataset on follistatin gene therapy outcomes will be licensed to biotech companies using a three-tier model, each with a corresponding fee and royalty structures. This data solves a critical problem for companies entering the pet longevity market: endpoint selection risk. Clinical trials often fail from selecting the wrong measurements. Dog Year’s dataset will reveal which degenerative conditions respond best to follistatin therapy, and which metrics are best to focus on in later therapy trials.
The DAO's token economy directly links data generation to value capture. Contributors (clinics, researchers, pet owners) earn tokens. Reserve tokens fund future trials and incentivize long-term follow-up data submission - creating an increasingly valuable longitudinal dataset that will augment the DAO’s ultimate goal of commercializing treatments across multiple regulatory environments.
## Additional information extracted from relevant pages
<fetched_info>
""" https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_17_44_PM_4881847691.png
Skipped image/binary URL (https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_17_44_PM_4881847691.png) - likely not text content
"""
""" https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_18_15_PM_87edcdef16.png
Skipped image/binary URL (https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_18_15_PM_87edcdef16.png) - likely not text content
"""
""" https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_18_37_PM_a71079da0b.png
Skipped image/binary URL (https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/Screenshot_2025_08_27_at_4_18_37_PM_a71079da0b.png) - likely not text content
"""
""" [Creator profile on Virtuals Protocol](https://api.virtuals.io/api/profile/0xe1490A9Cb6B077CD611e8a7e5427dae526381569)
{
"data": {
"id": 499177,
"displayName": null,
"bio": null,
"avatar": null,
"userSocials": [
{
"id": 563780,
"provider": "metamask",
"walletAddress": "0xe1490A9Cb6B077CD611e8a7e5427dae526381569",
"metadata": null
}
],
"socials": null
}
}
"""
</fetched_info>
<full_details>
{
"id": 37312,
"uid": "0daaf238-f950-40f6-8e37-706d23679f8f",
"createdAt": "2025-08-27T20:22:11.543Z",
"walletAddress": "0xe1490A9Cb6B077CD611e8a7e5427dae526381569",
"name": "Dog Years DAO",
"description": "Can we add years to dogs' lives, and life to their years? Dog Years will lead decentralized clinical trials in pursuit of extending canine healthspan, creating a future where dogs and their humans share longer, healthier lives together.",
"sentientWalletAddress": null,
"category": "IP MIRROR",
"role": "INFORMATION",
"daoAddress": null,
"tokenAddress": null,
"virtualId": null,
"status": "UNDERGRAD",
"symbol": "DOG",
"lpAddress": null,
"veTokenAddress": null,
"totalValueLocked": null,
"virtualTokenValue": null,
"holderCount": null,
"mcapInVirtual": null,
"preToken": "0xCfAbd6ddE4d38275cb44BdF4C8EF300f9B665521",
"preTokenPair": "0x8be41BbB3CD29A7eE44d717c781391268D85465C",
"aidesc": null,
"firstMessage": null,
"socials": null,
"tbaAddress": null,
"chain": "BASE",
"mainVirtualId": null,
"top10HolderPercentage": null,
"level": 1,
"valueFx": 0,
"priceChangePercent24h": 0,
"volume24h": 0,
"mindshare": null,
"migrateTokenAddress": null,
"lpCreatedAt": null,
"stakingAddress": null,
"agentStakingContract": null,
"merkleDistributor": null,
"isVerified": false,
"airdropMerkleDistributor": null,
"isDevCommitted": false,
"tokenUtility": "",
"showFounderVideo": false,
"roadmap": "Q3 2025: Virtuals Token Launch\n\nQ3 2025: Pilot Study (US) Recruitment Begins\n\nQ4 2025: Pilot Study for Follistatin Begins\n\n2026: Pilot Study Concludes - Data Licensed to Strategic Partners\n\n2027: Decentralized, Global Trials for Combination Therapies",
"additionalDetails": "Team & Community\n\n### Tristan Roberts\n\nReed College, Roote Fellow\n\nA notable biohacker and DeSci evangelist, his work on a HIV gene therapy was covered in Netflix's Unnatural Selection. He co-founded the gene therapy company Minicircle, overseeing their clinical trial in Prospera, after working in the DAO/LLC space.\n\n[](https://www.linkedin.com/in/tristan-roberts-932b2923/)[](http://twitter.com/aitherick)\n\n### Emmanuel Harel Bijaoui\n\nUniversity of College London (Masters of Engineering)\n\nEmmanuel Bijaoui is the founder and CEO of Treat, a decentralized contract research organization (CRO) revolutionizing clinical trials in pet health. He previously worked as a dementia researcher and led bioinformatics at a human microbiome startup.\n\n[](https://www.linkedin.com/in/emmanuel-bijaoui/)[](https://x.com/emmanuelBHarel)\n\n### Brandy Nunez\n\nDVM, Western University of Health Sciences MS, Microbiology Sam Houston State University\n\nA veterinary practicioner and analog astronaut, Brandy practices outside of LA. She is excited to see if this treatment can help the older dogs she sees, and if the first treatment might help astronauts as well.\n\n[](https://www.linkedin.com/in/brandy-l-nunez-dvm-51b6a89b/)",
"overview": "Degenerative disorders cascade: reduced mobility triggers muscle loss, adiposity gain, metabolic decline, and chronic inflammation. All of these, in turn, reduce lifespan.\n\n\n\nFollistatin gene therapy offers a breakthrough approach with multiple mechanisms of action. A single administration could provide relief for months. By inhibiting myostatin and activin, follistatin reduces inflammatory cytokines, preserves muscle tissue, and supports cartilage integrity. This shifts treatment from symptom management to addressing underlying aging mechanisms.\n\n\n\nCanines are an ideal translational model for human aging. They naturally develop osteoarthritis like humans, share our environment, and experience similar age-related frailty syndromes. We believe that a combination of treatments will drive the most meaningful longevity gains, and that it is on us to develop new ways of performing science to vet them.\n\nBy breaking the feedback loop between inflammation and systemic aging, we aim to create effective canine longevity interventions that will inform human therapeutic development.\n\n\n\nValue Capture Model\n\nDog Years DAO will convert clinical data into sustainable value through tiered licensing. The initial dataset on follistatin gene therapy outcomes will be licensed to biotech companies using a three-tier model, each with a corresponding fee and royalty structures. This data solves a critical problem for companies entering the pet longevity market: endpoint selection risk. Clinical trials often fail from selecting the wrong measurements. Dog Year’s dataset will reveal which degenerative conditions respond best to follistatin therapy, and which metrics are best to focus on in later therapy trials.\n\nThe DAO's token economy directly links data generation to value capture. Contributors (clinics, researchers, pet owners) earn tokens. Reserve tokens fund future trials and incentivize long-term follow-up data submission - creating an increasingly valuable longitudinal dataset that will augment the DAO’s ultimate goal of commercializing treatments across multiple regulatory environments.",
"image": {
"id": 51067,
"name": "37312_099eef48-dccc-41f4-a8d0-970b3c9d845b.jpg",
"alternativeText": null,
"caption": null,
"width": 400,
"height": 400,
"formats": {
"thumbnail": {
"ext": ".jpg",
"url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/thumbnail_37312_099eef48_dccc_41f4_a8d0_970b3c9d845b_d844158fd1.jpg",
"hash": "thumbnail_37312_099eef48_dccc_41f4_a8d0_970b3c9d845b_d844158fd1",
"mime": "image/jpeg",
"name": "thumbnail_37312_099eef48-dccc-41f4-a8d0-970b3c9d845b.jpg",
"path": null,
"size": 6.96,
"width": 156,
"height": 156
}
},
"hash": "37312_099eef48_dccc_41f4_a8d0_970b3c9d845b_d844158fd1",
"ext": ".jpg",
"mime": "image/jpeg",
"size": 26.39,
"url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/37312_099eef48_dccc_41f4_a8d0_970b3c9d845b_d844158fd1.jpg",
"previewUrl": null,
"provider": "aws-s3",
"provider_metadata": null,
"createdAt": "2025-08-27T20:16:46.156Z",
"updatedAt": "2025-08-27T20:16:46.156Z"
},
"genesis": null,
"stats": {
"contributionsCount": 0,
"contributorsCount": 0,
"contributionVersions": [],
"totalStakeAmount": "0.0",
"stakerCount": 0,
"validatorCount": 0
},
"characterDescription": "",
"projectMembers": [
{
"id": 32171,
"isAccepted": true,
"title": "Owner",
"createdAt": "2025-08-27T20:15:55.400Z",
"updatedAt": "2025-08-27T20:15:55.400Z",
"walletAddress": "0xe1490A9Cb6B077CD611e8a7e5427dae526381569",
"virtual": {
"id": 37312,
"creator": {
"id": 499177
}
},
"user": {
"id": 499177,
"socials": null,
"bio": null,
"avatar": null,
"walletAddress": "0xe1490A9Cb6B077CD611e8a7e5427dae526381569"
}
}
],
"tokenomics": [],
"tokenomicsStatus": {
"hasUnlocked": true,
"daysFromFirstUnlock": 0
},
"multichainAgents": []
}
</full_details>
Investment info last updated: Aug 27, 2025 20:23